|
|
Arecor Limited was established to exploit the extensive experience of the founders in engineering solutions for novel applications of proteins and other biologics for emerging healthcare needs. Arecor’s origins lie in Unilever Research and Insense Limited, a spinout of Unilever, which develops advanced woundcare and dermatology products. The stabilization technology originally applied by Insense to its product pipeline was acquired by Arecor and redirected to the biopharmaceutical and diagnostic sector offering protection to biologicals against degradation during long term storage and damage caused by exposure to ionizing radiation typically used in sterilization. Since its acquisition Arecor has substantially expanded the protein stabilization technology and successfully applied it to a wide range of biopharmaceuticals, medical devices and diagnostics, building significant partnerships with a number of major pharmaceutical and biotechnology companies.
|
|
|
|
Arecor is based at Colworth Park near Bedford in the United Kingdom and employs staff with expertise in protein formulation and analysis, manufacture and regulatory approval. It has extensive in-house analytical capabilities and access to the facilities of Unilever Research and Cambridge University.
|
|
|
|
The first commercial application of Arecor's protein stabilization technology is a novel woundcare dressing, Oxyzyme™, developed by Insense and approved in the EU and Canada.
Unilever Ventures is the lead investor of Arecor.
|
|
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
